Hypertrophic Cardiomyopathy Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of Hypertrophic Cardiomyopathy consistent with current US and European guidelines
Ability to perform an upright treadmill cardiopulmonary exercise test
Agreement to abide by contraceptive requirements

Exclusion Criteria:

Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
Women who are pregnant, planning to become pregnant or lactating
Participation in another clinical study involving a test product or invasive medical device within 28 days (or within 5 elimination half-lives of the respective test product, whichever is longer), prior to first dosing

Study is for people with:

Hypertrophic Cardiomyopathy

Phase:

Phase 2

Estimated Enrollment:

67

Study ID:

NCT04826185

Recruitment Status:

Completed

Sponsor:

Imbria Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

Imbria Investigational Site
La Jolla California, 92093, United States
Imbria Investigational Site
Los Angeles California, 90048, United States
Imbria Investigational Site
San Francisco California, 94143, United States
Imbria Investigational Site
Chicago Illinois, 60611, United States
Imbria Investigational Site
Boston Massachusetts, 02111, United States
Imbria Investigational Site
Burlington Massachusetts, 01805, United States
Imbria Investigational Site
Saint Louis Missouri, 63110, United States
Imbria Investigational Site
Morristown New Jersey, 07960, United States
Imbria Investigational Site
New York New York, 10016, United States
Imbria Investigational Site
Charlotte North Carolina, 28203, United States
Imbria Investigational Site
Portland Oregon, 97239, United States
Imbria Investigational Site
Houston Texas, 77030, United States
Imbria Investigational Site
Salt Lake City Utah, 84112, United States
Imbria Investigational Site
Oxford , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Hypertrophic Cardiomyopathy

Phase:

Phase 2

Estimated Enrollment:

67

Study ID:

NCT04826185

Recruitment Status:

Completed

Sponsor:


Imbria Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.